Analyst Conference Summaries

Biotechnology Investor Aids

Regeneron Pharmaceuticals
REGN

conference date: May 4, 2017 @ 5:30 AM Pacific Time

Regeneron Down 15% From 52-Week High: Buy? [April 9, 2014]
Regeneron Pipeline Worth Tens Of Billions In Market Capitalization [September 9, 2013]

Analyst Conference Notes by William P. Meyers
2017
 
 
 
May 4, 2017
 
 
 
2016
05/05/2016
08/04/2016
11/04/2016
02/09/2017
2015
05/07/2015
08/04/2015
11/04/2015
02/09/2016
2014
05/08/2014
08/05/2014
11/04/2014
02/10/2015
2013
not available

08/06/2013
11/05/2013
 02/11/2014

Regeneron (REGN) is a biotechnology company currently providing Eylea for Wet Macular Degeneration, Arcalyst for Cryopyrin-Associated Periodic Syndromes (CAPS), and Zaltrap for metastatic colorectal cancer.

Regeneron web site
Regeneron investor relations page

Note that I owned Regeneron stock from June 24, 2014 to January 10, 2017


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMD
 AMGN
 BIIB
 BIND
 CLDX
 CELG
 EPZM
 GILD
 GLYC
 HNSN
 INO
 INTC
 ISRG
 JUNO
 MACK
 MCHP
 MYL.
 NVDA
 PLX
 REGN
 SGEN
 XLNX
 XLRN

 

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. Before making or terminating an investment you should always verify any factual basis of your decision.

Copyright 2017 William P. Meyers